ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, ...
ENDRA Life Sciences Inc. (NDRA) is a healthcare medical-diagnostics company focused on improving clinical ultrasound capability. Its core technology is Thermo Acoustic Enhanced UltraSound (TAEUS®), a proprietary ultrasound approach intended to enhance how clinicians can interrogate tissue properties. The company’s imaging premise is based on emitting sound waves and analyzing ...ENDRA Life Sciences Inc. (NDRA) is a healthcare medical-diagnostics company focused on improving clinical ultrasound capability. Its core technology is Thermo Acoustic Enhanced UltraSound (TAEUS®), a proprietary ultrasound approach intended to enhance how clinicians can interrogate tissue properties. The company’s imaging premise is based on emitting sound waves and analyzing echo information related to internal body components (such as tissues, organs, and blood), with TAEUS® specifically positioned to support more informative measurements than conventional ultrasound in targeted use cases.
A key commercial emphasis highlighted for ENDRA is liver disease. ENDRA states that it is focused on early detection of liver disease, and it offers TAEUS® as a way to measure fat in the liver. This is important because hepatic fat measurement can be relevant in clinical assessment pathways for conditions such as nonalcoholic fatty liver disease. In addition to liver-focused imaging, the company describes applications that include temperature monitoring during thermoablative surgical procedures, vascular imaging, and assessment of tissue perfusion—suggesting that its platform concept is broader than a single diagnostic endpoint.
From a product and commercialization perspective, ENDRA also references offering/using other imaging modalities alongside enhanced ultrasound (e.g., computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound) to help clinicians visualize internal anatomy and support treatment guidance and diagnosis of conditions such as fractures, cancers, heart disease indicators, or internal bleeding. While the detailed commercial packaging varies by indication and region, ENDRA’s technology orientation is consistent: improve the diagnostic and procedural information available to healthcare providers using advanced ultrasound.
Regulatory and market progress is represented by the mention that TAEUS® is CE-marked for sale in Europe. This implies that the company is engaged in bringing the technology to market in at least some jurisdictions beyond the U.S., aligning with the company’s ongoing development and adoption efforts.
Operationally, ENDRA is a small public company. Publicly available datasets cited alongside the overview indicate approximately 9 full-time employees (and up to low-teens total employees including part-time roles), placing it in the 0–100 employee range. Leadership is provided by Alexander Y. Tokman, who serves as CEO (and has long association with the company through board and leadership roles).
Financially, the provided valuation and operating metrics suggest a development-stage or early commercialization profile, with negative profitability measures (e.g., negative return on assets/equity and negative free cash flow in the snapshot provided). In such contexts, cost control, continued research and product validation, regulatory/clinical work, and commercialization execution typically drive spending priorities (such as technology refinement, clinical evidence generation, and expansion of sales/partners). The company also indicates collaboration activity, including a research collaboration agreement with General Electric Company, which can support technology development, validation, and potential dissemination through industry relationships.
Overall, ENDRA’s “wishes” and strategic direction can be inferred from its focus areas: broaden healthcare access to better ultrasound-based diagnostic information, establish and expand clinical and regulatory acceptance for TAEUS®, and continue scaling adoption—particularly in liver-disease screening/assessment where early detection and improved measurement are central goals.
